首页> 美国卫生研究院文献>other >Ecdysteroids Sensitize MDR and Non-MDR Cancer Cell Lines to Doxorubicin Paclitaxeland Vincristine but Tend to Protect Them from Cisplatin
【2h】

Ecdysteroids Sensitize MDR and Non-MDR Cancer Cell Lines to Doxorubicin Paclitaxeland Vincristine but Tend to Protect Them from Cisplatin

机译:蜕皮类固醇使MDR和非MDR癌细胞系对阿霉素紫杉醇和长春新碱但倾向于保护他们免受顺铂的侵害

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ecdysteroids, analogs of the insect molting hormone, are known for their various mild, nonhormonal bioactivities in mammals. Previously, we reported that less-polar ecdysteroids can modulate the doxorubicin resistance of a multidrug resistant (MDR) mouse lymphoma cell line expressing the human ABCB1 transporter. Here, we describe the ability of 20-hydroxyecdysone (>1) and its mono- (>2) and diacetonide (>3) derivatives to sensitize various MDR and non-MDR cancer cell lines towards doxorubicin, paclitaxel, vincristine, or cisplatin. Drug IC50 values with or without ecdysteroid were determined by MTT assay. Compound >3 significantly sensitized all cell lines to each chemotherapeutic except for cisplatin, whose activity was decreased. In order to overcome solubility and stability issues for the future in vivo administration of compound >3, liposomal formulations were developed. By means of their combination index values obtained via checkerboard microplate method, a formulation showed superior activity to that of compound >3 alone. Because ecdysteroids act also on non-ABCB1 expressing (sensitive) cell lines, our results demonstrate that they do not or not exclusively exert their adjuvant anticancer activity as ABCB1 inhibitors, but other mechanisms must be involved, and they opened the way towards their in vivo bioactivity testing against various cancer xenografts.
机译:蜕皮类固醇是昆虫蜕皮激素的类似物,因其在哺乳动物中的各种轻度,非激素生物活性而闻名。以前,我们报道极性较小的蜕皮类固醇可以调节表达人ABCB1转运蛋白的多药耐药(MDR)小鼠淋巴瘤细胞系对阿霉素的耐药性。在这里,我们描述了20-羟基蜕皮酮(> 1 )及其单-(> 2 )和双丙酮化物(> 3 )衍生物对各种物质敏感的能力。 MDR和非MDR癌细胞系趋向于阿霉素,紫杉醇,长春新碱或顺铂。通过MTT测定法测定有或没有蜕皮甾体的药物IC50值。化合物> 3 使除顺铂外的所有细胞系均对每种化疗药物敏感,顺铂的活性降低了。为了克服溶解性和稳定性问题,用于将来化合物> 3 的体内给药,开发了脂质体制剂。通过棋盘微孔板法获得的组合指数值,该制剂显示出优于单独的化合物> 3 的活性。由于蜕皮类固醇也作用于不表达ABCB1的(敏感)细胞系,因此我们的研究结果表明,它们没有或不专门发挥其作为ABCB1抑制剂的佐剂抗癌活性,但是必须参与其他机制,它们为体内途径开辟了道路。针对各种癌症异种移植物的生物活性测试。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号